Stock comparison

INSMvsREGN

Insmed IncvsRegeneron Pharmaceuticals Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

INSM

Insmed Inc

$144.48

-26.63%

Biotechnology$35.0BNASDAQ

REGN

Regeneron Pharmaceuticals Inc

$766.02

+3.34%

Biotechnology$79.2BNASDAQ

60-day price, rebased to 100

INSM -8.45% · REGN +1.98%

Round-by-round

INSM 1·REGN 5

EdgeREGN

Valuation upside

-90.50% vs -22.60% to DCF fair value

EdgeINSM

Balance-sheet strength

Altman Z 9.81 vs 7.40

EdgeREGN

Fundamental quality

Piotroski 4.00 vs 5.00 (of 9)

EdgeREGN

Growth + margins

Rule-of-40 -92.80 vs 27.20

EdgeREGN

60-day momentum

-8.45% vs +1.98% price return

EdgeREGN

Market-cap liquidity

$35.0B vs $79.2B

Verdict

Across6categories,REGNtakes the edge with5wins to1. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onINSMorREGN

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.